VYNE Therapeutics Announces Special Dividend Ahead of Yarrow Bioscience Merger

VYNE Therapeutics has declared a special cash dividend, estimated at $16.5 million, which is conditional on the successful completion of its proposed merger with Yarrow Bioscience. The dividend, approximately $0.38 per share, is expected to be paid around July 24, 2026, following stockholder approval. This financial move is part of the ongoing merger process between the two companies.